Guy Hopgood

Guy Hopgood

Director

Guy is Director binnen het client consulting team van bfinance, gevestigd in Chicago. Hij was eerder werkzaam in het Private Markets research team, gevestigd in Londen, waar hij zich richtte op infrastructuur, vastgoed en andere strategieën zoals landbouw en hout. Guy kwam in 2015 bij bfinance van JLT Investment Consulting, waar hij Investment Consultant en Head of Alternatives Manager Research was en klanten adviseerde over portefeuilleconstructie en managerselectie in alternatieve activaklassen. Hij is afgestudeerd in Economie aan het Rollins College en heeft een deel van zijn studie doorgebracht in Shanghai, China.


More insights from the team:

bfinance’s quarterly report in February 2025: read the team’s latest insights on institutional investor activity, risk appetite, market developments and asset manager performance across all major...

The ‘Impact Private Debt’ sector has undergone a significant phase of expansion during the past two years. This report presents an overview of currently available strategies, while an illustrative...

‘Energy transition’ tailwinds should, it is often argued, boost the prices of particular commodities in the years ahead.

With an eye on recent difficulties in real estate portfolios, we ask: what has separated high-performing real estate managers from their weaker counterparts? And should investors consider adjusting...

Asset owners are now grappling with fundamental tensions within equity portfolio design. The runaway performance of tech titans has led to fears of market over-concentration. At the same time,...

A new survey of more than 300 investors (Global Asset Owner Survey, November 2024) indicates that more than 40% believe ‘like-for-like’ fees for Private Equity managers have decreased in the past...

A secular macroeconomic transition has created an unenviable series of choices—and potential traps— for pension funds, insurers, endowments, foundations, family offices and other ‘asset owners’...

Private debt investors are eyeing apparently superior returns in healthcare lending, with funds’ net IRR targets suggesting a premium of more than 300bps versus conventional direct lending...